Detail akcie Macrogenics online

Business Summary: MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MacroGenics Inc revenues decreased 17% to $108.3M. Net loss increased 17% to $60.5M. Revenues reflect Revenue From Collaborative Agreements decrease of 36% to $66.9M, Product revenue, net decrease from $14.3M to $0K, Government Contract decrease from $1.4M to $0K. Higher net loss reflects Interest and other expense increase from $1.1M to $4.2M (expense).